The Blood Test That Could Change Cancer Screening: What to Know About MCEDs

Currently, modern medicine relies on a fragmented, organ-by-organ approach to cancer screening. In the United States, routine preventative screenings are only recommended for five types of cancer: breast, cervical, colorectal, lung, and prostate. This leaves a massive diagnostic blind spot. The majority of cancer deaths are caused by malignancies that have no standard screening protocol, such as pancreatic, ovarian, and liver cancers, which are often only discovered after they have metastasized and become difficult to treat.[5]

A new technology known as multi-cancer early detection (MCED) is poised to fundamentally alter this landscape. Often referred to as a "liquid biopsy," an MCED test requires only a single vial of blood to screen for dozens of different cancers simultaneously. With the U.S. Food and Drug Administration (FDA) currently evaluating the first of these tests for premarket approval, the medical community is preparing for what could be the most significant shift in oncology in decades.[1]

The science driving MCEDs relies on the natural life cycle of cells. As cells in the body die, they shed tiny fragments of their genetic material into the bloodstream. Tumors do the same, releasing what is known as circulating tumor DNA (ctDNA). For years, researchers struggled to isolate these microscopic needles in the haystack of healthy DNA flowing through the circulatory system.[3]

The breakthrough came not just from sequencing the DNA, but from analyzing its "methylation patterns." Methylation involves chemical tags attached to DNA that act like a barcode, turning certain genes on or off. Because different tissues in the body have distinct methylation signatures, cancer alters these patterns in recognizable ways.

By applying advanced machine learning algorithms to these methylation barcodes, MCED tests can answer two critical questions: Is there a signal of cancer present in the blood? And if so, what is the likely tissue of origin? This allows doctors to pinpoint whether a positive signal is coming from the lungs, the esophagus, or the lymphatic system, streamlining the subsequent diagnostic search.[2]

Several companies are racing to bring these tests to the mainstream. GRAIL, a healthcare company that pioneered the technology, currently offers its Galleri test, which screens for over 50 types of cancer. Exact Sciences, known for its Cologuard test, is developing a rival MCED called Cancerguard. Currently, these tests are available as Laboratory Developed Tests (LDTs) and cost roughly $700 to $1,000 out-of-pocket, as they are not yet broadly covered by insurance.[3][4]

The push for FDA approval hinges on massive clinical trials designed to prove the tests' real-world efficacy. The most closely watched of these is the NHS-Galleri trial, a monumental study conducted in partnership with England's National Health Service. The trial enrolled over 140,000 asymptomatic participants aged 50 to 77, making it the largest randomized, controlled trial of an MCED test to date.

When GRAIL presented the latest data from the NHS-Galleri trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the results offered a nuanced picture of the technology's current capabilities. The trial did not meet its primary endpoint, which was a statistically significant reduction in combined Stage III and IV cancer diagnoses within a one-year follow-up window.

However, the secondary endpoints revealed exactly the kind of shift oncologists have been hoping for. By the third round of annual screening, the test drove a 26 percent reduction in Stage IV (metastatic) diagnoses for 12 prespecified, highly lethal cancers. Catching these cancers before they spread to other organs is critical, as the survival rate plummets once metastasis occurs.

Conversely, the trial showed a 16 percent increase in Stage I and II diagnoses for those same cancers. This stage-shift—moving diagnoses from late-stage to early-stage—means that more patients are finding their cancers when surgical removal and localized treatments are still highly effective options.

Despite these encouraging metrics, the broader clinical community remains cautious about rolling out MCEDs to the general population. The primary concern revolves around the tests' Positive Predictive Value (PPV). While MCEDs boast an exceptionally high specificity—meaning they have a false positive rate of less than 1 percent—the rarity of cancer in asymptomatic people skews the predictive math.

In current trials, the PPV of MCED tests hovers between 40 and 50 percent. In practical terms, this means that if a patient receives a "cancer signal detected" result, there is roughly a coin-flip chance that extensive follow-up testing will actually locate a tumor. For the other half of patients, the signal may be a false alarm, or a sign of a benign biological process that the test misinterpreted.

This dynamic creates a complex dilemma for primary care physicians. A positive MCED result triggers a "diagnostic odyssey," often requiring full-body PET scans, MRIs, and sometimes invasive tissue biopsies to find the suspected cancer. This process can induce severe psychological distress—often termed "scanxiety"—and generate massive downstream costs for the healthcare system.[6]

Furthermore, researchers emphasize that the ultimate benchmark for any cancer screening tool is whether it actually reduces overall cancer mortality. Finding a slow-growing tumor early does not always save a life if that tumor was never destined to become lethal, a phenomenon known as overdiagnosis. The National Cancer Institute has launched its own Vanguard trial to rigorously assess whether MCEDs definitively save lives over the long term.[2]

As the FDA weighs these benefits and risks, policymakers are already preparing for a future where MCEDs are a standard part of preventative care. In early 2026, Congress passed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. This legislation establishes a dedicated pathway for Medicare to cover the cost of MCED tests starting in 2028, contingent upon FDA approval.[6]

For now, medical guidelines are clear: MCED tests are not a replacement for proven, standard-of-care screenings like mammograms or colonoscopies. They are designed to be an additive tool, specifically targeting the dozens of aggressive cancers that currently slip through the cracks of modern medicine. If approved, they represent the first step toward a new paradigm—one where a single blood draw could offer a comprehensive window into a patient's health.[5]